The National Institutes of Health has awarded Lucigen a $150,000 Small Business Innovation Research grant to be used to develop research tools with the potential to improve human health. The grant provides funding for the development of improved tools for “RNA-Seq” techniques used in next generation sequencing applications. RNA-Seq methods are employed in order to study gene regulation and expression; however, current methods suffer from poor accuracy and inherent bias. Lucigen’s portfolio of high-fidelity reverse-transcriptase polymerases, along with the company’s experience in constructing low-bias DNA libraries, will be utilized to create new methods for accurate RNA-Seq applications. The result will enable scientists to gain clearer understanding of gene regulation and subsequently apply this to human health.
Horizon Discovery announces collaboration with major pharmaceutical company on single cell RNAseq-linked CRISPR screening
26 days ago
10X Genomics secures partners to develop applications for its new single cell feature barcoding technology
August 1, 2018